Search Results
Nov 11, 2025, 10:30 ET Wastewater Surveillance Market worth $1.22 billion by 2030 with 6.7% CAGR | MarketsandMarkets™
industry toward faster, more sensitive, and more affordable solutions. This includes progress in molecular diagnostics, next-generation sequencing (NGS), biosensors, multiplex PCR assays, and AI-powered data analytics for trend forecasting. The availability of portable, field-ready testing kits and cloud-based
More news about: MarketsandMarkets
Nov 11, 2025, 09:36 ET GenomOncology Partners with Glioblastoma Foundation to Accelerate Precision Glioblastoma Brain Cancer Treatment
treatment options for patients. The Glioblastoma Foundation's laboratory is among a small, select group of facilities nationwide offering this specialized NGS testing capability. "GenomOncology delivered on an ambitious timeline—having their platform fully operational with our team trained
More news about: GenomOncology
Nov 11, 2025, 09:00 ET Complete Genomics Highlights Clinical Research Sequencing Solutions and Partnerships at AMP 2025
G400 sequencers with integrated iCare reporting. ABL Diagnostics: A cost-efficient, multiplexed NGS approach for next-generation infectious disease testing, further detailed in ABL's accompanying poster presentation.
More news about: Complete Genomics
Nov 11, 2025, 08:01 ET SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS). Together, the technologies will provide speed, scalability, and flexibility, enabling clinical researchers to turn NGS data into actionable insights within a single streamlined process. AVITI and AVITI24 users
More news about: SOPHiA GENETICS
Nov 11, 2025, 08:01 ET SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS). Together, the technologies will provide speed, scalability, and flexibility, enabling clinical researchers to turn NGS data into actionable insights within a single streamlined process. AVITI and AVITI24 users
More news about: SOPHiA GENETICS
Nov 10, 2025, 12:15 ET Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
multimedia:https://www.prnewswire.com/news-releases/illumina-protein-prep-delivers-groundbreaking-precision-in-ngs-proteomics-for-more-than-40-customers-ranging-from-academic-institutions-to-large-national-biobanks-302610407.html
More news about: Illumina, Inc.
Nov 10, 2025, 11:50 ET New England Biolabs® announces a full lineup of events supporting the AMP 2025 Annual Meeting & Expo in Boston, MA
real-world example of how a hospital system applied NEBNext® reagents for a critical diagnostics workflow. "NEB bespoke solutions: collaborating on a custom NGS rapid heme panel to serve the Boston community" will be presented by Dr. Harrison Tsai, M.D., Ph.D., Associate Director of Molecular Informatics, Center
More news about: New England Biolabs, Inc.
Nov 10, 2025, 10:00 ET Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
(CDx) test for Roche's ROZLYTREK® (entrectinib). This milestone marks China's first next-generation sequencing (NGS)-based pan-solid tumor NGS CDx test, and it is also the first approved assay for detecting NTRK1/2/3 gene fusions.
More news about: Geneseeq Technology Inc.
Nov 10, 2025, 07:30 ET Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-Generation Sequencing (NGS) library preparation. By integrating AI-driven design and high-throughput assays, Fapon actively leverages its AI-enabled enzyme
More news about: Fapon
Nov 07, 2025, 10:30 ET Preimplantation Genetic Testing Market worth $1,135.0 million by 2030 with 10.5% CAGR | MarketsandMarkets™
analysis. The next-generation sequencing (NGS) segment accounted for the largest share of the preimplantation genetic testing market in 2024 and is expected to maintain its dominance during the forecast period. The market's growth is driven by the increasing adoption of NGS for comprehensive chromosomal and
More news about: MarketsandMarkets
Nov 05, 2025, 06:03 ET AMP 2025: DNAe to unveil latest data from world's first NGS-based, fully automated sample-to-result diagnostic platform
Whole Blood using the LiDia-SEQ™ Platform: The First, NGS-Based Sample-to-Result Platform Category: Infectious Diseases Presenter: Stephanie Barnes – Scientist, NGS Assay Development, DNAeDate:
More news about: DNAe
Nov 05, 2025, 05:01 ET Companion Diagnostics Market Worth USD 15.6 Bn by 2030 Growing at 12.4% CAGR, says Mordor Intelligence
Integration of Next-Generation Sequencing (NGS) Technologies The use of NGS-based testing platforms is transforming how we discover biomarkers and perform multiplex testing. By enabling comprehensive genomic profiling across multiple mutations, NGS helps reduce both turnaround time
More news about: Mordor Intelligence Private Limited
Nov 04, 2025, 09:00 ET WesBanco Announces Full Redemption of 6,000,000 Depositary Shares, Each Representing a 1/40th Interest in a Share of Its 6.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A
WHEELING, W.Va., Nov. 4, 2025 /PRNewswire/ -- WesBanco, Inc. (Nasdaq/NGS: WSBC) ("WesBanco") today announced that on November 15, 2025 it will redeem all of the 150,000 issued and outstanding shares of its 6.75% Fixed-Rate
More news about: WesBanco, Inc.
Nov 04, 2025, 08:30 ET MiDOG Expands Scientific Advisory Board with the Appointment of Dr. Curtis Huttenhower, Dr. Micah Kohles, and Dr. Krista A. Keller
microbiome science, practical clinical insight, and zoological medicine leadership, strengthening MiDOG's mission to deliver next-generation sequencing (NGS) diagnostics that turn complex microbial data into clear, decision-ready insights for veterinarians across all animal species.
More news about: MiDOG Animal Diagnostics
Nov 04, 2025, 06:45 ET SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
(CDx) assay Signed two major new partnerships with AstraZeneca in Q3 to (1) develop an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway and (2) leverage SOPHiA GENETICS's
More news about: SOPHiA GENETICS
Oct 30, 2025, 16:30 ET ePlus Announces Second Quarter and Six Month Fiscal Year 2026 Earnings Release Date and Conference Call
HERNDON, Va., Oct. 30, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Oct 30, 2025, 10:00 ET Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research
simple, rapid NGS kitted panels," said Joseph Goffreda, Automation Specialist for Pillar Biosciences. "The oncoReveal NGS Kits powered by Pillar's proprietary SLIMamp® enrichment chemistry are perfectly suited for high-throughput automation on the Hamilton STAR, simplifying NGS workflows and
More news about: Pillar Biosciences, Inc.
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
Early-stage developability: process validation begins during discovery Data-driven design: AI and NGS redefine antibody and protein engineering Multimolecular integration: ADCs, PROTACs, and AOCs
More news about: Beijing Tsingke Biotech Co., Ltd.
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
Early-stage developability: process validation begins during discovery Data-driven design: AI and NGS redefine antibody and protein engineering Multimolecular integration: ADCs, PROTACs, and AOCs
More news about: Beijing Tsingke Biotech Co., Ltd.
Oct 28, 2025, 10:07 ET Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
sequential similarity between HCAb VH sequences and those of conventional (H2L2) antibodies. Harbour BioMed's HCAb generation model is trained on 9 million NGS-derived HCAb sequences and extensive public data. Using a fine-tuned protein large language model, it enables de novo generation of high-potential
More news about: Harbour BioMed
Oct 28, 2025, 10:00 ET Signios Bio and Illumina Announce Winners of the Illumina-Signios Bio Proteomics Grant Program
Program. The program was established to advance proteogenomic research through access to the Illumina Protein Prep 9.5K™, the industry's largest NGS-based proteomics panel.
More news about: Signios Bio
Oct 24, 2025, 13:02 ET Sampled and AutoGen Announce Partnership for Specialized Nucleic Acid Extraction and Multiomic Workflows
Efficient nucleic acid extraction remains a critical foundation for advanced applications like next-generation sequencing (NGS), proteomics, and cell-based discovery. Sampled performs a wide range of extractions internally as part of its integrated "sample-to-discovery"
More news about: Sampled
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
Cholangiocarcinoma Foundation. "The eNRGy trial results are encouraging, and they underscore how critical comprehensive molecular testing, notably tissue-based RNA NGS, is to ensure that patients with rare drivers such as NRG1 fusions are identified and can potentially have access to targeted treatments."
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 10:00 ET Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting
highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp®
More news about: Pillar Biosciences, Inc.
Oct 17, 2025, 02:53 ET MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
and lymphomas. For diagnostics, we utilize a broad range of methods, including conventional histology, immunohistochemistry, immunophenotyping, and NGS. Our molecular diagnostics also extend to the analysis of solid tumors, enabling personalized therapy in these cases. With clear diagnoses, we help clinically
More news about: Quest Diagnostics